NEOVACS ANNOUNCES THAT THE POSITIVE RESULTS OF ITS PROOF OF CONCEPT IN ALLERGIES WITH IL-4 / IL-13 KINOID HAVE TRIGGERED THE FIRST PAYMENT OF THE ANR GRANT

Ads

You May Also Like

Genocea to Present at Stifel 2017 Healthcare Conference

CAMBRIDGE, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company ...

ThromboGenics Business Update – H1 2018

Press release6 September 2018Regulated Information Positive Topline Results for Diabetic Eye Disease Portfolio Shareholder ...